Marko Poglitsch

Marko Poglitsch is an experienced professional in the biotechnology sector, currently serving as CEO of Attoquant Diagnostics GmbH since October 2012. Prior to this role, Marko held the position of Project Head at APEIRON Biologics, contributing to significant projects within the company. Marko began a career in research as a PhD student at Medical University of Vienna (MUW), where studies were conducted from 2007 to 2010.